In previous studies, we observed that a high proportion of donor-derived CD4 þ T cells expressing the chemokine receptor 7 (CCR7) was a major determinant of acute GVHD, without interfering with the incidence of other post-transplant outcomes, especially relapse and nonrelapse mortality rates. Here, we investigated in vitro the impact of partially selective CD4 þ /CCR7 þ T lymphocytes on acquired anti-infective immune response in 10 donors who underwent G-CSF-primed PBSC collection. Similar quantitative and functional proliferative reactions were observed in lymphocyte cultures in the presence of adenovirus and pp65 Ags with unmanipulated and partially depleted donor samples. No responses were observed in the presence of human T-cell lymphotropic virus type 1 used as a negative control. These results complete the proof of concept needed to build a clinical trial investigating partially selective CD4 þ /CCR7 þ T cell-depleted allo-SCT.
INTRODUCTION
Allo-SCT offers a curative therapeutic approach in a wide range of otherwise fatal hematological diseases. 1, 2 The success largely depends on transplanted T cells, but alloreactive T cells from the graft can also initiate acute GVHD (aGVHD), [3] [4] [5] [6] [7] a major complication responsible for the high incidence of morbidity and mortality.
Initial trials with T cell-depleted allo-SCT were effective in reducing aGVHD, but with an increase of relapse incidences and infectious complications. 3 Although variable success in the reduction of aGVHD incidence and/or severity without alteration of GVL responses could be obtained with the use of manipulated grafts either ex vivo [7] [8] [9] [10] [11] [12] [13] or in vivo by using, as part of conditioning regimens, polyclonal Abs such as antithymocyte globulin 14 or MoAb against CD52, 15 separation of GVHD from GVL responses and anti-infective effect is still an elusive goal. Although panlymphocyte depletion resulted in significantly less GVHD, there was increased incidence of viral and opportunistic infections and relapse, leading to an absence of significant improvement on overall survival.
In the previous two clinical prospective studies that investigated the impact of infused donor-derived T-cell subsets on patients' outcome, we observed that a high proportion of CD4 þ T cells expressing chemokine receptor 7 (CCR7; naive and central memory) is a major determinant of aGVHD, without interfering with the incidence of other post-transplant complications, mainly relapse. 16 These results confirm experimental data showing that cells with an effector memory phenotype do not induce GVHD if purified from unprimed donors, while preserving immune reconstitution. 17, 18 In a murine model using CCR7
À / À donor T cells, Coghill et al. 19 demonstrated superior allo-SCT outcome due to a reduced incidence of GVHD with preserved GVL responses. Taken together, all these studies suggest that determining the proportion of CCR7-expressing CD4 þ T cells in the allograft would provide an important predictive indicator of aGVHD, and thus CD4 þ /CCR7 þ T-cell partial selective depletion may represent a viable treatment option for the prevention of aGVHD in the clinical setting.
Although donor-derived T-cell partial and selective depletion would have a little impact on the ability of T naive cells to mount robust GVL responses, no study has specifically investigated the role of such manipulation on anti-infective immunity. Here, we show that reducing the proportion of CD4 þ /CCR7 þ T cells in PBSC graft does not alter donor-required anti-infective responses.
This study represents a step forward in proof-of-concept data and completes the background needed to set up a first-in-human partially selective CD4 þ /CCR7 þ T cell-depleted allo-SCT phase I clinical trial.
MATERIALS AND METHODS Donors
The study design has been approved by the ethics committee of the Lille University Hospital, and all donors included have given their informed consent. As, in France, the use of G-CSF is not allowed in healthy minor donors, all of our 10 PBSC donors were older than 18 years. All donors were tested for antihuman T-cell lymphotropic virus type 1 (HTLV1), anti-CMV and antiadenovirus (ADV), and donor serologic results are summarized in Table 1 . For each donor included (seven men and three women), 1 mL of final product of PBSC was processed in the laboratory within 6 h.
Multiparameter flow cytometric analysis
Graft samples were stained without further separation shortly after collection. Directly conjugated Abs to CD45, CD3, CD4, CD8, CD45RA and isotype controls were from Beckman Coulter (Galway, Ireland) and CCR7 was from R&D Systems (Minneapolis, MN, USA). After staining (concentrations according to the manufacturers' instructions), relative proportions of þ partially depleted PBMCs per well were stimulated for a week in U-bottom 96-well plates (NUNC, Roskilde, Denmark) with 1 mg/ml of each Ag (peptivator-CMVpp65 mixed with peptivator CMV IE-1-premium grade at equal proportion, AdV peptides (peptivator-AdV hexon from Miltenyi Biotec, Bergisch Gladbach, Germany) or HTLV1 Tax (VWR International, Fontenay-sous-bois, France).
Proliferation assay
Responses to Ags were determined by two approaches. For evaluating divided T cells by carboxyfluorescein succinimidyl ester dilution, PBMCs were labeled at day 0 with 1 mmol/L of carboxyfluorescein succinimidyl ester (Cell-Trace CFSE; Life Technologies, Saint-Aubin, France) and then cultured for 7 days before harvesting and staining with CD3-APC Ab. For measured [3H]-thymidine incorporation after 6 days, each culture was pulsed for the last 18 h with.5 mCi per well (18.5 kBq per well) of [3H]-thymidine and then harvested for microbeta scintillation counting (PerkinElmer, Waltham, MA, USA).
Measurement of cytokine production
Cultured cells stimulated for 7 days with the different viral Ags were tested for their IFN-g capacity production by an IFN-g enzyme-linked immunosorbent spot assay. After 6 days of stimulation, each well was harvested and washed twice before returning to culture for an additional 20 h in immunospot plates coated with a MoAb to IFN-g. IFN-g spots were enumerated according to the manufacturer's instructions by using the TB Scan software (TB-SPOT TB, Oxford Immunotech, Oxford, UK). Means of duplicate wells were calculated and expressed as spots per well.
Statistical analysis
Values are expressed as mean and range. The Mann-Whitney U-test was used for all comparisons between values obtained before and after T-cell partial selective depletion for each virus and between values obtained with HTLV1 and ADV or CMV, respectively. SPSS software (SPSS, Chicago, IL, USA, II, v19) was used for all calculations.
RESULTS
The PBSC collections of seven men and three women were analyzed. The median proportion of CD4 þ T cells among samples was 32% (range, 22-49%) and that of CD4 þ /CCR7 þ T cells among CD4 þ T cells was 83% (range, 75-93%). As shown in Table 1 , all the donors were seronegative for the HTLV1 and seropositive for the ADV. Only three donors were CMV seronegative.
Proliferative indexes by quantitative method using carboxyfluorescein succinimidyl ester at day 7 As shown in Figure 1 , the mean percentage of divided CD3 þ lymphocytes at day 7 using carboxyfluorescein succinimidyl ester in the presence of ADV, pp65 and HTLV1. Dtpop ¼ partially CD4 þ /CCR7 þ T cell-depleted samples; Tpop ¼ unmanipulated sample.
observed in almost all cultures before and after T-cell partial selective depletion except for donors with negative CMV serostatus. Indeed, a mean of 7.0% (range, 0.2-38%) of divided CD3 þ lymphocytes was observed in unmanipulated samples and 9.5% (range, 0.2-55.9%) in depleted ones (P ¼ 0.46).
No proliferation was observed in the presence of HTLV1 Ag that served as a negative control.
The difference in proliferation index was statistically significant between cultures in the presence of either CMV or ADV and in the presence of HTLV1, be it before or after manipulation (Po0.001).
Proliferative index by quantitative method using tritiated thymidine 3H at day 7 As shown in Figure 2 , there were no differences between unmanipulated samples and those cultured after depletion for either ADV or CMV. Results are expressed as c.p.m. for the considered virus per c.p.m. for the HTLV1 considered as negative control for unmanipulated and depleted samples, respectively.
Measure of INF-g capacity secretion indexes using enzyme-linked immunosorbent spot method at day 7 INF-g secretion measurements were conducted on cultures exposed to the ADV. The mean numbers of spots was 174 (range, 39-303) and 44 (range, 1-104) for unmanipulated and depleted samples, respectively. In the same way, for cultures placed in the presence of pp65 Ag (only for seropositive donors), the spot number was similar between both groups, and the mean number of spots was 113 (range, 46-451) and 111 (range, 46-385), respectively, before and after selective partial T-cell depletion.
As depicted in Table 2 , the differences were significant when compared with HTLV1 results for both CMV and ADV cultures in unmanipulated and partially depleted samples (Po0.001).
As expected, no secretion was observed in donors whose CMV serostatus was negative. Figure 3 illustrates results of enzymelinked immunosorbent spots in the presence of pp65 Ag in all cultures before and after the depletion regardless for all donors. CD4 þ CCR7 þ T-cell depletion for allo-SCT B Choufi et al might reflect the predominant distribution of alloreactive T cells in the naive and central memory subsets, as described both for naive CD4 þ T cells in humans 20 and in experimental models for naive 17, 18, 21 and central memory subsets. 22 As CCR7 expression is critical for T cell entry into secondary lymphoid organs, CCR7 þ naive and central memory cells are subsets that can migrate to lymph nodes where they can meet host (allo) APCs and initiate GVHD. In agreement with the threestep model of GVHD pathogenesis, 23 tracking donor cells during GVHD has demonstrated that they first partition and expand in host lymphoid organs and then their progeny infiltrates target organs. 24 Accordingly, CCR7 is necessary for the control of effector cells in alloimmune responses. 25 Therefore, inhibition of adhesion and cell-trafficking molecules such as CCR7 and CD62L could be a promising approach to reduce the incidence and severity of aGVHD in allo-SCT, as those molecules have a well-established role in GVHD development. 16, [18] [19] [20] 26, 27 Taking into account the coexpression of cell-trafficking molecules on the same subsets of T lymphocytes, and the redundancy phenomena encountered in cell-trafficking blockade methods, [28] [29] [30] we have preferred to explore a partially selective approach of CD4 þ /CCR7 þ T cell depletion rather than a CCR7 blockade one.
Although the preservation of antitumor effect was demonstrated in the absence of a CCR7 þ lymphocyte setting, 19 the results of our current study provide some evidences that partial CD4 þ /CCR7 þ T-cell depletion of donor PBSC does not alter acquired antiviral immunity at least vis-à-vis the two principal viruses that reactivate the most after allo-SCT and that are responsible for high post-transplant morbidity and mortality.
These results confirm what others and we have observed in vivo that CD4 þ T lymphocytes expressing the trafficking Ag CCR7 or CD62L were more likely committed to aGVHD reactions rather than to GVL or anti-infective responses. 16, 26 Although the number of IFN-g spots obtained in a partial CD4 þ CCR7 þ T-cell depletion setting was inferior to the one obtained with unmanipulated sample in the presence of ADV, the difference with the number of spots obtained in the presence of HTLV1 was statistically significant and the immune response to ADV was still satisfactory for appropriate antiviral responses. Indeed, the minimum required for a positive reaction in our laboratory is at least 20 spots.
We are aware that from the pathophysiological standpoint acquired anti-infective immunity transfer is mainly insured by CD8 þ memory T lymphocytes rather than by CD4 þ naive or central memory T lymphocytes. [31] [32] [33] However, the net antiinfective responses are affected by several complex T-cell subsets that might have a role in determining the final response. [34] [35] [36] [37] [38] [39] On the other hand, there is always multidirectional cooperation between T-lymphocyte subsets even in secondary anti-infective reactions. 39 As a matter of fact, the aim of our work was to ensure the absence of any manipulation-related alteration of the acquired anti-infective immune response toward virus, be it related to cell sorting techniques or to an alteration of the cooperation between CD4 þ and CD8 þ T cells following depletion that would diminish the proportion of CD4 þ /CCR7 þ T cells. One may question why we chose to investigate secondary reactions rather than primary ones. Indeed, measuring the capacity of graft-containing T-cell subsets to induce anti-infective primary reactions was not the goal, as post-transplant immune reconstitution is usually ensured by donor stem cellderived lymphopoiesis in recipient and not by the infused lymphocytes with graft. 40, 41 The major issue of post-transplant immune reconstitution and primary anti-infective reactions should be addressed in all further partially selective transplantation approaches.
In conclusion, this study demonstrates the preservation of acquired antiviral immunity to PBSC after partially selective T-cell depletion. Our results along with what has been already demonstrated in the field give ground to a rational use of this approach in clinical trial.
